Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds
The DOI matches its Crossref record.
Abstract
A class of antidiabetes drugs is associated with an increase in safety alerts for pancreatitis and pancreatic cancer, a new analysis has found. The Institute for Safe Medication Practices, a US non-profit organisation that promotes the safe use of drugs, monitored reports of serious adverse events to the US Food and Drug Administration from 1 July 2011 to 30 June 2012 concerning five glucagon-like peptide-1 (GLP-1) based agents (exenatide, liraglutide, sitagliptin, saxagliptin, and linagliptin) used to lower blood glucose concentrations. It compared these against the rates of adverse event reporting for a control group of drugs comprising other drugs used to treat type 2 diabetes (three sulfonylureas and metformin) and drugs for treating other diseases. GLP-1 …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
Thomsen, R. W., Pedersen, L., Møller, N., Kahlert, J., Beck-Nielsen, H., & Sørensen, H. T. (2015) · Diabetes Care · doi:10.2337/dc13-2983 · Cited by 89
“Thus, there is a concern that incretins may cause pancreatitis and pancreatic cancer in humans (6,7), although the evidence is controversial (8).”
BackgroundThe French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0544-0 · Cited by 70
“8 times more likely with respectively GLP-1 analogs and DPP-4 inhibitors than with control antihyperglycemic drugs (sulfonylureas and metformin) [13, 14].”
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Metadata
- Authors
- Cohen, D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2013-04-23
- Volume
- 346
- Issue
- apr23 1
- Pages
- f2607-f2607
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W1987548551
- Cited by
- 24
- References
- 0
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. https://app.cochat.ai/papers/10.1136/bmj.f2607
- The paper
- Cohen, D. (2013). Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. BMJ. https://doi.org/10.1136/bmj.f2607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.